Abstract
Many regenerative medicine technologies have now entered the clinical realm with the help of biomaterials. Biomaterials, in conjunction with therapeutic stem or immune cells or cell products, are used to engineer tissues for in vivo testing platforms (organs‐on‐chips) or clinical use. However, biomaterials can also be used to stimulate in situ tissue regeneration to avoid adverse immune reactions. In ophthalmology, human donor corneas have served well for corneal transplant surgery. However, the massive shortage of suitable donor tissue combined with the expense and technical challenges of eye banking leaves a substantial proportion of the world's population without access to treatment. Here, we discuss the development of novel biomaterials for corneal implants that stimulate in situ tissue regeneration and the pathway to getting these into clinical trials. The results of clinical and pre‐clinical trials will be discussed.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
